Did United Therapeutics beat or miss consensus estimates last quarter?

What is United Therapeutics's latest dividend and current dividend yield?

What guidance did United Therapeutics's management provide for the next earnings period?

What is United Therapeutics's gross profit margin?

What were the key takeaways from United Therapeutics’s earnings call?

What is the revenue and EPS growth rate for United Therapeutics year over year?

What is the market's earnings forecast for United Therapeutics next quarter?

What does United Therapeutics do and what are its main business segments?

- **2027 Product Breakthroughs**: Launching three category-defining therapies addressing cough, dosing frequency, and IPF efficacy gaps.
- **Revenue Growth Track Record**: $3B+ in 2025, 11% YoY growth, on track for $4B+ run rate by end-2027.
- **Market Leadership**: Tyvaso DPI maintains 24% YoY growth despite competitor entry; Q4 referrals at pre-competitor levels.
- **Clinical Momentum**: TETON 2 IPF trial showed 95.6mL FVC improvement; super prostacyclin unblinding imminent.

**【CEO Summary Section】**
- **Innovative Product Launches**: Announced three transformative products for 2027: a cough-reducing soft mist inhaler (Tresmi), a once-daily super prostacyclin pill, and a superior IPF treatment. These aim to address key patient pain points (cough, dosing frequency, efficacy).
- **Revenue Growth Commitment**: Reaffirmed double-digit revenue growth, targeting a $4 billion annual run rate by end-2027. Current product portfolio (Tyvaso DPI, Orenitram) is driving this growth, with new launches as upside.
- **Strategic Initiatives**: Highlighted AI-driven digital lung model partnerships, xenotransplantation progress (6-patient Xeno trial enrollment by summer 2026), and Skunkworks innovation pipeline (e.g., PRN inhalers, advanced pills).

**【CFO Financial Commentary】**
- **2025 Financial Performance**: Total revenue reached $3 billion (11% YoY growth), with Q4 revenue of $790 million (7% YoY). Tyvaso DPI grew 24% YoY, driven by 80mcg cartridge adoption and referral rates at pre-competitor launch levels.
- **Product Differentiation**: Introduced 96mcg/112mcg combination kits and 80mcg cartridges, enhancing dosing flexibility and patient convenience. Orenitram/Remodulin data showed early high-dose treprostinil benefits in PAH.

**【Q&A Key Highlights】**
- **IPF Trial Confidence**: Leigh Peterson expressed high confidence in TETON 1 results mirroring TETON 2 (95.6mL FVC improvement), citing similar baseline characteristics and robust efficacy.
- **Market Competition**: Michael Benkowitz reported Tyvaso DPI retaining leadership despite Yutrepia launch, with Q4 referrals at pre-competitor levels and Q2 sequential growth expected.
- **Product Pipeline Timing**: Tresmi filing in 2026, super prostacyclin unblinding next week, and IPF approval filing post-TETON 1 readout (June 2027 launch).

United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript

- **Record Q3 2025 Results**: $800M revenue (+7% YoY), driven by Tyvaso DPI and Orenitram growth.
- **$4B 2027 Run Rate Target**: Ambitious goal reflecting confidence in IPF and PH-ILD expansion.
- **Innovative Product Launches**: 80-microgram Tyvaso DPI cartridge and RemunityPRO pump enhance patient convenience.
- **Ralinepag Partnership Potential**: Long patent life (2040) and synergistic effects position for strategic deals.
- **TETON 2 IPF Impact**: Unblinded data shows unprecedented benefits, with physician interest in dual PH/IPF treatment.

**【CEO Summary Section】**
- United Therapeutics reported record total revenues of $800 million for Q3 2025, a 7% year-over-year increase, driven by Tyvaso and Orenitram sales.
- CEO Martine Rothblatt highlighted the successful enrollment of three Phase III trials and the unblinded results for pulmonary fibrosis (IPF), which showed unprecedented treatment benefits.
- The company is targeting a $4 billion annual revenue run rate by 2027, with a focus on expanding into IPF and PH-ILD markets.
- Rothblatt emphasized the potential for partnerships with large pharma companies (e.g., Merck, J&J) to leverage ralinepag's long patent life (2040) and its synergistic effects with other therapies.

**【COO Summary Section】**
- Michael Benkowitz reported continued double-digit growth for Tyvaso DPI, with no material impact from competitor YUTREPIA's launch.
- The new Tyvaso DPI 80-microgram cartridge enables 15 breaths in a single dose, offering superior dosing flexibility compared to competitors.
- Launch of 96- and 112-microgram combination kits aims to improve access for high-dose patients.
- Remodulin's new RemunityPRO pump enhances patient convenience and home therapy initiation.
- Q3 2025 results reflect strong execution across commercial, clinical, and operational fronts.

**【Q&A Key Highlights】**
- **IPF and PH Synergy**: Analysts asked about the potential for increased IPF diagnoses and Tyvaso sales following TETON 2 data. COO Michael Benkowitz noted early physician interest but cautioned it's too early to measure impact.
- **Ralinepag Partnership Potential**: CEO highlighted ralinepag's best-in-class efficacy, long patent life, and formulation flexibility for combination therapies. She expressed openness to partnerships with large pharma companies.
- **Revenue Guidance Clarity**: CEO clarified the $4 billion run rate target includes both PH and IPF growth, with Q3 2025 results underscoring confidence in achieving this by 2027.
- **Commercial Dynamics**: COO confirmed Tyvaso DPI maintains market share in both PAH and PH-ILD, with patient shipments and prescriber breadth metrics remaining strong post-YUTREPIA launch.
- **Regulatory Updates**: EVP of Product Development Leigh Peterson confirmed TETON-PPF trial enrollment is ~50% complete and the company is engaging with FDA to expedite IPF regulatory review.


United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call Transcript

- **Record Growth**: Q2 2025 revenue of $799M (+12% YoY), driven by 22% YoY jump in Tyvaso DPI sales
- **Pipeline Momentum**: TETON 2 IPF study set to report September 2025; xenotransplantation programs advancing
- **Strategic Capital Allocation**: $1B share buyback authorized amid strong cash flow (~$1.5B/year)
- **Competitive Confidence**: Tyvaso DPI maintains leadership despite new DPI entrant
- **Long-Term Vision**: 3 growth waves positioning UTHR for decades of expansion

**【CEO Summary Section】**
- United Therapeutics reported record Q2 2025 revenue of $799 million, marking 12 consecutive quarters of double-digit year-over-year growth.
- The Tyvaso franchise remains a key driver, with Tyvaso DPI revenue up 22% YoY to $315 million and nebulized Tyvaso showing strong demand.
- Management emphasized three growth waves: 
  1. **Foundation Wave**: Continued expansion of Tyvaso, Orenitram, and Unituxin.
  2. **Innovation Wave**: Upcoming TETON 2 IPF study readout (September 2025) and ADVANCE outcome study in PAH.
  3. **Revolution Wave**: Xenotransplantation programs (kidney, liver, heart) with first transplant expected in EXPAND-UKidney study.
- Board authorized $1 billion share buyback program, reflecting confidence in long-term prospects.

**【CFO Financial Commentary】**
- Q2 2025 total revenue: $799 million (+12% YoY)
- Tyvaso DPI revenue: $315 million (+22% YoY)
- Orenitram and Unituxin both achieved double-digit YoY growth
- Strong operating cash flow (~$1.5 billion annually) supports capital allocation flexibility
- No near-term capital constraints despite buyback authorization

**【Q&A Key Highlights】**
1. **Utrepia Launch Impact**: 
   - Competitor DPI launched but no material impact on Tyvaso DPI script volume
   - Tyvaso DPI maintains leadership with superior tolerability and deposition profile (2.6 micron particles)
   - Long-term confidence in Tyvaso DPI's product differentiation

2. **TETON 2 Study Details**: 
   - 597-patient Phase III IPF study outside U.S./Canada
   - Primary endpoint: 52-week change in FVC
   - 80% powered to detect 80mL improvement vs. placebo
   - Centralized PFT reading and rigorous protocol adherence to minimize variability
   - Data readout expected September 2025

3. **TPIP Concerns**: 
   - Questioned statistical methods and baseline imbalances in Phase IIb PAH study
   - Doubts about clinical superiority over Tyvaso
   - Long timeline (~7+ years) for potential market entry
   - Minimal impact on UTHR business even if approved

4. **Buyback Rationale**: 
   - Shares undervalued vs. growth prospects
   - Strong balance sheet ($1.5B annual cash flow)
   - Flexibility to repurchase up to $1B through March 2026
   - No impact on R&D or M&A capabilities

United Therapeutics (UTHR)-30 Jul 25-2025 Q2 Earnings call transcript

- **Record Q1 Growth**: $794M revenue (+17% YoY), 9th straight record quarter.
- **Pipeline Momentum**: 5 registration studies, 3 xeno organs in preclinical, FDA-approved UTHYMOKIDNEY IND.
- **Sustainable Capital Allocation**: $1B+ annual cash flow, 1/3 spent on R&D, 1/3 on manufacturing, 1/3 returned to shareholders.
- **Market Leadership**: 4 delivery methods for treprostinil, only 40% of PAH patients treated with prostacyclins.
- **Upcoming Catalysts**: TETON IPF data (Q2), ralinepag launch (Q4), once-daily Tyvaso in preclinical.

**【CEO Opening Remarks】**
- Q1 2025 revenue reached $794 million, up 17% YoY, marking the 9th consecutive quarter of record revenue.
- Core products (Tyvaso, Orenitram, Remodulin) drove double-digit growth for 11 straight quarters.
- Pipeline expansion includes 5 registration-phase studies, 3 xeno organs nearing clinical trials, and FDA-approved UTHYMOKIDNEY IND.
- Financial discipline maintained: <50% of prior-year revenue spent on R&D/SG&A, $1B+ annual operating cash flow.

**【COO Commercial Update】**
- Tyvaso DPI/nebulizer split stable at 2/3:3/3 new patient starts.
- Price increases implemented Q1, but Part D redesign obligations offset benefits.
- No gross-to-net impacts in Q1; catastrophic coverage obligations phase-in.
- TETON data in IPF expected to expand Tyvaso into orphan market with 10-year exclusivity.

**【Q&A Key Takeaways】**
1. **Xenotransplantation Progress**: 
   - UTHYMOKIDNEY trial to enroll same patient population as 10-gene kidney study.
   - Learnings from Ms. Looney case: refined immunosuppression protocols, infection management strategies.
2. **Competitive Landscape**: 
   - Only 40% of PAH patients on prostacyclins; UT leads with 4 delivery methods (oral, parenteral, DPI, nebulizer).
   - Once-daily Tyvaso in preclinical; ralinepag expected to launch Q4 2025.
3. **Capital Allocation**: 
   - 1st priority: R&D ($100M+ Q1 spend on pipeline).
   - 2nd: Manufacturing (DPI facility expansion).
   - 3rd: Share buybacks ($1B in 2024; no plans to resume until after TETON readout).
   - No interest in M&A; focused on internal innovation.
4. **TPIP Competition**: 
   - Doubt Insmed's once-daily treprostinil will match Tyvaso efficacy.
   - UT developing NCE once-daily alternative with faster regulatory path.

**【Growth Outlook】**
- Core portfolio: 10-15% YoY growth (double-digit for 12+ quarters).
- TETON-positive scenario: $1B+ annual sales in IPF (2025 launch).
- Ralinepag: Best-in-class sGC stimulator targeting PAH/HFpEF.

United Therapeutics (UTHR)-30 Apr 25-2025 Q1 Earnings call transcript

- **Record Revenue Growth**: 24% YoY total revenue in 2024, driven by double-digit growth across all major products.
- **Pipeline Milestones**: First xeno kidney transplant expected mid-2025; Phase 3 IPF data and ralinepag enrollment completion targeted for 2025.
- **Capital Allocation**: $1B returned to shareholders; strategic investments in manufacturing, clinical scale, and acquisitions.
- **Market Resilience**: Tyvaso maintains growth despite new contracts; IPF and xeno transplant programs position for multibillion-dollar opportunities.

**【CEO Overview】**
- United Therapeutics achieved record revenue for the 3rd consecutive year in 2024, driven by strong commercial performance across all major products (Tyvaso, Remodulin, Orenitram, Unituxin).
- Key pipeline progress:
  - UKidney clinical trial (xeno kidney transplant) received FDA IND clearance; first transplant expected mid-2025.
  - Inhaled treprostinil (TETON 2) targeting IPF with Phase 3 data expected H2 2025; ralinepag (once-daily oral prostacyclin) enrollment completion targeted for late 2025.
- Capital allocation: $1B returned to shareholders via share buyback in 5Q; continued investment in manufacturing (Tyvaso DPI facility), clinical scale DPF expansion, and strategic acquisitions (IVIVA, Miromatrix).

**【COO Commercial Update】**
- Q4 2024 total net revenue growth: 20% YoY; full year 2024 growth: 24% YoY.
- Product highlights:
  - Tyvaso: $416M (19% YoY), record patient shipments despite gross-to-net deductions from new payer contracts.
  - Orenitram: $108M (28% YoY), 50% of starts from Remodulin transitions.
  - Remodulin: $135M (17% YoY), new Remunity Pro pump launch planned Q4 2025.
  - Unituxin: $68M (25% YoY), strong US market penetration.
- Contracting strategy: Additional rebates locked in for Tyvaso to maintain parity with competitors; believes base for future growth is set.

**【Q&A Key Themes】**
1. **Pipeline Execution**:
   - UKidney trial: 6-patient Cohort 1 with 12-week safety review; endpoints include 6-month graft survival and safety metrics.
   - IPF program: Treprostinil's multifactorial mechanism could complement existing therapies; TETON 2 data expected H2 2025.
2. **Market Dynamics**:
   - Impact of Hyperion (VRTX's PAH therapy): Unlikely to materially affect Tyvaso growth as prostacyclins remain critical in PAH treatment.
   - Part D redesign: 90% of patients now commercial; minimal expected impact on 2025 growth trajectory.
3. **Competitive Positioning**:
   - Tyvaso contracting: Additional rebates positioned company for long-term payer parity; focus on clinical differentiation (e.g., once-daily ralinepag).
   - Xeno transplant: Leading clinical and manufacturing infrastructure (3 DPFs planned) positions for regulatory leadership.

Actual											3.12	2.41	3.84	2.19	0.61	3.65	3.42	3.51	5.03	2.41	4.91	2.67	4.86	5.24	5.38	4.36	6.17	5.85	6.39	6.19	6.63	6.41	7.16	7.7
Forecast											2.7389	2.7729	2.8413	2.9513	3.0325	3.02	3.5925	3.58	3.6464	4.3893	3.9096	4.7224	4.5883	4.569	5.1019	4.1872	5.7425	6.5054	6.5233	6.3997	6.6964	7.295	7.3167	6.8712
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+13.91%	-13.09%	+35.15%	-25.80%	-79.88%	+20.86%	-4.80%	-1.96%	+37.94%	-45.09%	+25.59%	-43.46%	+5.92%	+14.69%	+5.45%	+4.13%	+7.44%	-10.07%	-2.04%	-3.28%	-0.99%	-12.13%	-2.14%	+12.06%

UTHR

UTHR fundamentals

UTHR Q4 2025 Earnings

Earnings Call

You can ask Aime

UTHR

UTHR fundamentals

UTHR Q4 2025 Earnings

Earnings Call

UTHR Earnings Call Summary for Q4/20259:00 AM on Feb 25, 2026

UTHR Earnings Call Summary for Q3/20259:00 AM on Oct 29, 2025

UTHR Earnings Call Summary for Q2/20259:00 AM on Jul 30, 2025

UTHR Earnings Call Summary for Q1/20259:00 AM on Apr 30, 2025

UTHR Earnings Call Summary for Q4/20249:00 AM on Feb 26, 2025

You can ask Aime